Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
100 Results for "
SGLT
" in MedChemExpress (MCE) Product Catalog:
Products (100)
100 Results for "SGLT" in MCE Product Catalog:
Cat. No.: HY-180528
Target:
Research Areas:
SGLT2-IN-6 (Compound 101) is an orally active SGLT2 inhibitor with IC₅₀ values for SGLT2, SGLT1, and DPP4 of 0.8, 6.7, and 72 nM respectively. SGLT2-IN-6 controls blood sugar levels in diabetic rat models and increases the levels of active GLP-1. SGLT2-IN-6 can be used for the study of type 2 diabetes .
Cat. No.: HY-17638A
CAS No.: 1169392-27-1
Synonyms: DSP-3235 (sebacate); KGA-3235 (sebacate); GSK-1614235 (sebacate)
Target:
Research Areas:
Mizagliflozin sebacate (DSP-3235 sebacate) is a sodium-glucose cotransporter inhibitor with activity in improving vascular cognitive impairment caused by small vessel disease. Mizagliflozin sebacate improves blood flow and reverses vascular cognitive impairment by inhibiting neuronal SGLT1 activity. Mizagliflozin sebacate also showed the ability to increase the survival rate of IL-1β-treated PC12HS cells. Mizagliflozin sebacate promotes improvements in spatial learning and memory caused by small vessel disease in mouse models .
Cat. No.: HY-10450AR
CAS No.: 960404-48-2
Synonyms: BMS-512148 (2S)-1,2-propanediol, hydrate (Standard)
Target:
Research Areas:
Dapagliflozin ((2S)-1,2-propanediol, hydrate) (Standard) is the analytical standard of Dapagliflozin ((2S)-1,2-propanediol, hydrate). This product is intended for research and analytical applications. Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin ((2S)-1,2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury .
Cat. No.: HY-166652S
CAS No.: 2714418-84-3
Cat. No.: HY-178734
CAS No.: 1800115-22-3
Target:
Research Areas:
Janagliflozin is orally active and highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor (IC50=0.0058 μM for SGLT2 and 4.802 μM for SGLT1). Janagliflozin inhibits SGLT2 in the proximal renal tubules, reducing glucose reabsorption and promoting urinary glucose excretion (UGE) to lower blood glucose levels. Janagliflozin is promising for research of type 2 diabetes mellitus .
Cat. No.: HY-109092R
CAS No.: 1291094-73-9
Synonyms: LIK066 (Standard)
Target:
Research Areas:
Licogliflozin (Standard) is the analytical standard of Licogliflozin (HY-109092). This product is intended for research and analytical applications. Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor.
Cat. No.: HY-17604A
CAS No.: 1118567-48-8
Synonyms: EGT1442 diproline; EGT0001442 diproline; THR-1442 diproline
Target:
Research Areas:
Bexagliflozin diproline (EGT1442 diproline; EGT0001442 diproline; THR-1442 diproline) is an orally active and selective SGLT2 inhibitor with IC50 values of 0.002 μM and 5.6 μM for SGLT2 and SGLT1, respectively. Bexagliflozin diproline selectively inhibits SGLT2-mediated sodium-dependent glucose uptake. Bexagliflozin diproline induces saturable urinary glucose excretion in normal rats and dogs. Bexagliflozin diproline reduces blood glucose and HbA1c levels in db/db mice without affecting body mass or insulin level. Bexagliflozin diproline can be used for the research of type 2 diabetes mellitus, hypertensive stroke .
Cat. No.: HY-109144R
CAS No.: 1415472-28-4
Synonyms: DWP-16001 (Standard)
Target:
Research Areas:
Enavogliflozin (Standard) is the analytical standard of Enavogliflozin (HY-109144). This product is intended for research and analytical applications. Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor .
Cat. No.: HY-10449R
CAS No.: 898537-18-3
Synonyms: TS 071 (Standard)
Target:
Research Areas:
Luseogliflozin (Standard) is the analytical standard of Luseogliflozin (HY-10449). This product is intended for research and analytical applications. Luseogliflozin (TS 071) is a potent, selective, orally active sodium-dependent glucose cotransporter (SGLT) 2 inhibitor, with an IC50 of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC50, 3990 nM). Luseogliflozin has the protential for researching type 2 diabetes .
Cat. No.: HY-L040
1,172 compounds
Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.
The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.
MCE Anti-diabetic Compound Library owns a unique collection of 1,172 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.
Cat. No.: HY-186207
CAS No.: 2408732-62-5
Target:
Research Areas:
Demethyl-LX2761 is a selective sodium-glucose cotransporter 1 (SGLT1) inhibitor. Demethyl-LX2761 can be used for the research of type 2 diabetes .
Cat. No.: HY-109018R
CAS No.: 946525-65-1
Target:
Research Areas:
Velagliflozin (Standard) is the analytical standard of Velagliflozin (HY-109018). This product is intended for research and analytical applications. Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity.
Cat. No.: HY-101782R
CAS No.: 1638851-44-1
Target:
Research Areas:
HSK0935 (Standard) is the analytical standard of HSK0935 (HY-101782). This product is intended for research and analytical applications. HSK0935 is a potent, highly selective and orally available SGLT2 inhibitor with an IC50 of 1.3 nM. Antihyperglycemic activities .
Cat. No.: HY-109018AR
CAS No.: 1539295-26-5
Target:
Research Areas:
Velagliflozin proline (Standard) is the analytical standard of Velagliflozin (proline) (HY-109018A). This product is intended for research and analytical applications. Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .
Cat. No.: HY-109018BR
CAS No.: 1661838-94-3
Target:
Research Areas:
Velagliflozin proline hydrate (Standard) is the analytical standard of Velagliflozin (proline hydrate) (HY-109018B). This product is intended for research and analytical applications. Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .
Cat. No.: HY-180784
Target:
Research Areas:
Hypoglycemic agent 4 (Compound 5b) is a tetrahydroacridine derivative with orally active hypoglycemic activity. Hypoglycemic agent 4 has a good binding affinity for the key diabetic targets: DPP-IV, SGLT1, and GLUT2. Hypoglycemic agent 4 can inhibit glucose diffusion. Hypoglycemic agent 4 can reduce fasting blood sugar in Streptozotocin (HY-13753)-induced diabetic rats and its effect is comparable to Gliclazide (HY-B0753). Hypoglycemic agent 4 can be used for research of type 2 diabetes .
Cat. No.: HY-166548S
CAS No.: 1233515-93-9
Synonyms: GSK189075-d7
Cat. No.: HY-P703207
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: SLC5A1; D22S675; Prev. SGLT1; Solute Carrier Family 5 (Sodium/Glucose Cotransporter), Member 1; Sodium/Glucose Cotransporter 1; Na(+)/Glucose Cotransporter 1; NAGT; Na+/Glucose Cotransporter 1; High Affinity Sodium-Glucose Cotransporter; Solute Carrier Fa
Species:
Human
Source:
HEK293
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
